Page 479 - Read Online

Du et al. TLRs in cancer

colorectal cancer. J Physiol Pharmacol 2009;60 Suppl 1:65-71. 50. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim
33. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver YJ. Intratumoral administration of TLR4 agonist absorbed into
disease: update. Hepatology 2008;48:322-35. a cellular vector improves antitumor responses. Clin Cancer Res
34. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, 2011;17:3984-92.
Karin M. Gender disparity in liver cancer due to sex differences in 51. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C,
MyD88-dependent IL-6 production. Science 2007;317:121-4. Davila E. When Toll-like receptor and T-cell receptor signals collide:
35. Husseinzadeh N, Davenport SM. Role of toll-like receptors in a mechanism for enhanced CD8 T-cell effector function. Blood
cervical, endometrial and ovarian cancers: a review. Gynecol Oncol 2010;116:3494-504.
2014;135:359-63. 52. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3
36. Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie can directly trigger apoptosis in human cancer cells. J Immunol
J, Cadranel J, Wislez M. Expression of TLR9 in tumor-infiltrating 2006;176:4894-901.
mononuclear cells enhances angiogenesis and is associated with a 53. Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet
worse survival in lung cancer. Int J Cancer 2014;134:765-77. B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, Salaun B,
37. Luo Y, Jiang QW, Wu JY, Qiu JG, Zhang WJ, Mei XL, Shi Z, Di JM. Renno T, Micheau O, Lebecque S. dsRNA induces apoptosis through
Regulation of migration and invasion by Toll-like receptor-9 signaling an atypical death complex associating TLR3 to caspase-8. Cell Death
network in prostate cancer. Oncotarget 2015;6:22564-74. Differ 2012;19:1482-94.
38. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, 54. Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer
Ziparo E, Riccioli A. Toll-like receptor 3 triggers apoptosis of human I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. Prognostic
prostate cancer cells through a PKC-alpha-dependent mechanism. and predictive value of DAMPs and DAMP-associated processes in
Carcinogenesis 2008;29:1334-42. cancer. Front Immunol 2015;6:402.
39. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, Sato 55. Jin Y, Wi HJ, Choi MH, Hong ST, Bae YM. Regulation of anti-
T, Morino-Koga S, Kai H. TLR3 induction by anticancer drugs inflammatory cytokines IL-10 and TGF-beta in mouse dendritic cells
potentiates poly I: C-induced tumor cell apoptosis. Cancer Sci through treatment with Clonorchis sinensis crude antigen. Exp Mol
2010;101:1610-7. Med 2014;46:e74.
40. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like 56. Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse
receptor 3 expressed by melanoma cells as a target for therapy? Clin DL. The role of toll-like receptors in colorectal cancer progression:
Cancer Res 2007;13:4565-74. evidence for epithelial to leucocytic transition. Front Immunol
41. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of 2014;5:429.
Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell 57. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best
proliferation and tumor growth. Cancer Res 2011;71:2466-75. frenemy in cancer immunotherapy. J Leukoc Biol 2013;93:847-63.
42. Li X, Liu D, Liu X, Jiang W, Zhou W, Yan W, Cen Y, Li B, Cao G, 58. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless
Ding G, Pang X, Sun J, Zheng J, Zhou H. CpG ODN107 potentiates JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of
radiosensitivity of human glioma cells via TLR9-mediated NF-kappaB immune surveillance. Cancer Res 2005;65:5009-14.
activation and NO production. Tumour Biol 2012;33:1607-18. 59. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue
43. Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, of the Drosophila Toll protein signals activation of adaptive immunity.
Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Nature 1997;388:394-7.
Bianco R, Tortora G. Toll-like receptor 9 agonist IMO cooperates with 60. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L,
everolimus in renal cell carcinoma by interfering with tumour growth Kroemer G, Galluzzi L. Trial watch: Toll-like receptor agonists for
and angiogenesis. Br J Cancer 2013;108:1616-23. cancer therapy. Oncoimmunology 2013;2:e25238.
44. Shi M, Zhang Y, Liu L, Zhang T, Han F, Cleveland J, Wang F, 61. Jinesh GG, Kamat AM. Redirecting neutrophils against bladder cancer
McKeehan WL, Li Y, Zhang D. MAP1S Protein Regulates the cells by BCG and Smac mimetic combination. Oncoimmunology
Phagocytosis of Bacteria and Toll-like Receptor (TLR) Signaling. J 2012;1:1161-2.
Biol Chem 2016;291:1243-50. 62. Bidnur S, Savdie R, Black PC. Inhibiting immune checkpoints for the
45. Yuminamochi E, Koike T, Takeda K, Horiuchi I, Okumura K. treatment of bladder cancer. Bladder Cancer 2016;2:15-25.
Interleukin-12- and interferon-gamma-mediated natural killer cell 63. Holcmann M, Drobits B, Sibilia M. How imiquimod licenses
activation by Agaricus blazei Murill. Immunology 2007;121:197-206. plasmacytoid dendritic cells to kill tumors. Oncoimmunology
46. Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, 2012;1:1661-3.
Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor 64. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D,
activities. Expert Opin Ther Targets 2013;17:481-3. Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J,
47. Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Menard S, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B,
Balsari A. Antitumor activity of the TLR-5 ligand flagellin in mouse Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K,
models of cancer. J Immunol 2006;176:6624-30. Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA
48. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-
R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances adjuvanted vaccine against cervical infection and precancer caused by
dendritic cell survival and promotes tumor antigen-specific T cell oncogenic HPV types (PATRICIA): final analysis of a double-blind,
priming: relation to central nervous system antitumor immunity. J randomised study in young women. Lancet 2009;374:301-14.
Immunol 2006;176:157-64. 65. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois
49. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, Goubar A,
Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Lebecque S, Pierres M, Rimoldi D, Romero P, Andre F. TLR3 as a
Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H. In biomarker for the therapeutic efficacy of double-stranded RNA in
vivo delivery of siRNA to immune cells by conjugation to a TLR9 breast cancer. Cancer Res 2011;71:1607-14.
agonist enhances antitumor immune responses. Nat Biotechnol 66. Chochi K, Ichikura T, Kinoshita M, Majima T, Shinomiya N, Tsujimoto
2009;27:925-32. H, Kawabata T, Sugasawa H, Ono S, Seki S, Mochizuki H. Helicobacter
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ December 29, 2016 469